It’s another promising result from one of the dozens of bio-pharmaceutical companies trying to find treatments for fatty liver disease. Viking Therapeutics announced results from an early study of NAFLD patients that exceeded expectations yesterday, sending the stock soaring 122%.
Continue reading “Viking Therapeutics delivers promising results in NALFD trial”